Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jul 23, 2008 - ISENTRESS(R) (raltegravir), Merck's first-in-class HIV-1 integrase inhibitor, suppressed HIV-1 viral load and increased CD4 cell counts through 48 weeks of combination therapy with other...
SOPHIA ANTIPOLIS, France, July 24, 2008 /PRNewswire-FirstCall/ -- NicOx S.A. today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The...
- Nexavar is First Approved Systemic Therapy to Treat the Disease -
WAYNE, N.J. and EMERYVILLE, Calif., July 23, 2008 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that The New England...
Study results pending publication in July print edition of Clinical Chemistry, available on Web
INDIANAPOLIS, July 23, 2008 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide...
SAN FRANCISCO, July 23, 2008 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare...
Wilson H. Miller, Jr.
Professor – Department of Medicine
Division of Experimental Medicine
McGill University
NEW YORK, July 22, 2008--Arsenic Trioxide is a drug with an amazing impact on reversing the growth of acute promyelocytic leukemia...
BOSTON, July 23, 2008 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer...
CHICAGO, July 22, 2008—Women with sexual dysfunction caused by the use of antidepressants experienced a reduction in adverse sexual effects with use of sildenafil, commonly known as the erectile dysfunction medication Viagra, according to a study in...
Supplemental Findings Presented at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference
AUSTIN, Texas--(BUSINESS WIRE)--July 23, 2008--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of...
MONTEREY, Calif.--(BUSINESS WIRE)--Jul 23, 2008 - ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the...
SAN DIEGO, July 22, 2008 /PRNewswire/ -- Helicon Therapeutics, Inc. today announced results from a study of memory formation in Macaque monkeys, showing that its drug, HT-0712, enhances long-term memory formation. HT-0712 already has shown a...
NEW YORK, July 21, 2008--New, groundbreaking research reveals the drug abiraterone could treat up to 80 percent of patients with aggressive and previously drug resistant prostate cancer, according to a study published in the Journal of Clinical...
M. D. Anderson scientists caution against targeting HMGB1 to treat other diseases
SMITHVILLE, Texas, July 21, 2008 – An abundant chromosomal protein that binds to damaged DNA prevents cancer development by...
- Data Describes Nimotuzumab's Unique Binding Properties Resulting In Superior Side-Effect Profile Compared To Other EGFR-Targeting Drugs -
MISSISSAUGA, ON, July 21 - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that...
NEW YORK--(BUSINESS WIRE)--Jul 22, 2008 - IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary therapies for the treatment of cancer and viral diseases, today announced preliminary findings from its...
(BUSINESS WIRE)--Jul 22, 2008 - ExpertSource:
TOPIC: Researchers found that 10 percent of what appeared to be healthy middle-aged people had suffered a silent stroke, according to an article by United Press International. Researchers, who reviewed...
The Lupusorb™ was demonstrated to be safe and effective in removing a harmful antibody from patients’ bodies.
JERUSALEM, Israel, July 21, 2008--Hadasit Bio-Holdings, (HBL) a subsidiary of Hadasit (the technology transfer company of the...
Ygiene(TM) Antimicrobial Has Been Found to Eradicate Clostridium Difficile (C. diff.) Spores in Seconds
NEWARK, N.J., July 22, 2008 /PRNewswire/ -- BioNeutral announces successful independent laboratory test results which showed that Ygiene(TM)...
LONDON, UK, July 22, 2008: BTG plc (LSE: BGC), the life sciences company, notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction in prostate specific...
Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer
SAN FRANCISCO, and YONGIN-SI, South Korea, July 22, 2008 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner...
More...Clinical Trial Results Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
